Introduction
Prion diseases are devastating neurological disorders that affect a variety of mammalian species including humans [1] . These degenerative diseases of the central nervous system primarily affect the brain leading to progressive dementia, debilitating motor dysfunction such as ataxia and ultimately to death in 4-6 months from the onset of the disease [2, 3] . The human prion diseases are distinguished in terms of their clinical and pathological manifestation. The three principal subgroups are familial CreutzfeldtJakob disease (fCJD), Gerstmann-Str€ ausslerScheinker (GSS) syndrome, and Familial Fatal Insomnia (FFI) [4, 5] . The sporadic Creutzfeldt-Jakob disease (CJD) is the most common form of the human prion diseases.
The cellular prion protein, PrP C , undergoes a process of mis-folding and aggregation leading to the transmissible spongiform encephalopathies. Therefore, this notoriously labile protein has remained the focal point of investigation by the scientific community for several decades [6] . In the 'protein only' hypothesis that has been proposed for the prion propagation process, the ubiquitously present PrP C undergoes a malicious conformational change into the pathogenic conformation, PrP Sc ; this leads to the onset of the devastating diseases. The nonpathogenic conformer PrP is an extracellular membrane-anchored glycoprotein that contains two unrelated domains; the N-terminal domain (residues 23-125) is flexible and unstructured whereas the folded globular C-terminal domain (residues 126-231) comprises two native antiparallel bstrands, b1 and b2 and three a-helices a1, a2, and a3.
On the other hand, its pathogenic isoform PrP Sc is an aggregated structure constituted mainly by elongated stacks of b-sheets [7] . These infectious PrP Sc particles also exhibit atypical physicochemical properties such as protease resistance, insolubility, and the propensity to polymerize into amyloid-like fibrillar structures. In the prion replication and propagation process, the infectious PrP Sc acts as a template that promotes its self-proliferation by recruiting the cellular prion molecules. This vicious cycle continues, leading to the formation of long fibril-like structures [8, 9] .
Several pharmacological chaperones have been developed in order to stabilize the prion protein in its native form, thereby preventing the toxic pathogenic conversion process [10] . The POM family of monoclonal anti-PrP antibodies can recognize a wide range of epitopes within the amino and the carboxy-terminal domains of the prion protein. The POM1 antibody, that recognizes regions surrounding the N-terminus of helix a1, perpetuates rapid toxicity in cerebellar organotypic cultured slice (COCS) assays leading to cell death [11] . The POM1 antibody recognizes residues on the segment connecting the b1-strand to the a1-helix, the N-terminus of the a1-helix and several residues on helix a3 [12] . The neurotoxicity of POM1 is not caused by the generation of infectious prion particles (PrP Sc ) [13] but seems to trigger similar pathways [14] suggesting that POM1 might be a prion-mimetic reagent. Extensive structural studies, however, showed that the binding of POM1 does not cause any major conformational distortions in the globular domain of the PrP C [12] . The POM2 antibody that recognizes the octapeptide repeat domain of the unstructured N-terminus prevents the POM1 induced toxicity in COCS. It was proposed that the binding of certain antibodies to the globular domain of the prion protein triggers toxicity that is somehow mediated by the octapeptide repeat domain.
Another noteworthy member of the POM family of monoclonal antibodies is the POM6 IgG which recognizes a distinct epitope of the structured domain in a similar way to that of the POM1 antibody. The most interesting functionality of POM6 is that despite having epitopes neighboring those of POM1, the POM6 antibody is innocuous to the cerebellar slices in a COCS assay [11] . A comparative structural characterization of the binding of POM6 Fab and POM1 Fab from the protein complex of mouse prion protein (PDB ID: 4H88) previously determined by our group might provide insight into the mis-folding prone motifs within the globular region of the prion protein. Here, we describe the molecular structure of the complex of the POM6 Fab antibody fragment with the C-terminal structured domain of the mouse prion protein (moPrP). We reveal that POM6 binding facilitates the formation of a stable hydrogen-bonding network within the mis-folding prone regions of the prion protein that could result in an arguably stronger globular domain with a more protected hydrophobic core. This study may help in identifying key segments of the prion protein that are suitable for the targeting of anti-prion therapeutics for the prevention of prion toxicity.
Results
Our initial attempts at cocrystallizing the POM6 Fab with the mouse prion protein structured domain having the residue range 117-231 were unsuccessful. We then changed the mouse prion construct, to residue 125-225 in which the flexible regions, consisting of residue ranges 117-124 and 225-231 were removed in the hopes that it would form better crystal packing. With these modifications in the moPrP construct, we successfully cocrystallized moPrP:POM6 Fab in the space group of P22 1 2 1 . The crystals diffracted to 1.83 A resolution and the asymmetric unit contained one molecule of the moPrP:POM6 Fab complex ( Fig. 1 and Table 1 ).
Overall structure of the protein complex moPrP: POM6 Fab
In the moPrP:POM6 Fab structure, all six of the CDRs of the POM6 Fab molecule have well-defined electron densities in the 2|F O |À|F C | map. All the six CDRs of POM6 Fab participate in interactions with the mouse prion structured domain. The heavy chain CDRs (CDR H1, residues 25-34; CDR H2, residues 49-60; CDR H3, residues 98-104) make more hydrogen-bonding and electrostatic interactions with the prion epitope compared to those of the light chain CDRs (CDR L1, residues 24-38; CDR L2, residues 54-60; CDR L3, residues 93-101). The shape complementarity scores between POM6 Fab and the prion protein calculated by the Sc program of the CCP4 suite [15] are 0.772 and 0.652 for the H and L chains, respectively, indicating a good complementarity. It is interesting to note that the POM6 Fab binds to all three of the helices of the structured domain of the prion protein. The residue range 125-224 of the prion protein in the moPrP:POM6 Fab complex could be well traced in the 2|F O |À|F C | electron density map. In agreement with the previously published crystal structures of the globular portion of the prion protein (e.g.,PDB ID: 1AG2), the POM6 Fab bound moPrP molecule has two b-strands (residues 127-129 in b1 and 161-163 in b2) and three a-helices (residues 143-155 in a1, 171-193 in a2 and 199-223 in a3) (Fig. 1) .
The crystal structure of the moPrP:POM6 Fab complex reveals that the POM6 Fab has a conformationdependent discontinuous epitope on the mouse prion protein. The POM6 Fab binding site has a surface area of 805 A 2 or 12.5% of the prion protein surface is solvent inaccessible. The amino-terminal region of helix a3 and the polypeptide chain connecting helixes a2 and a3 are the primary occupants of the cleft between the variable domains of the light and the heavy chains of the POM6 Fab (Fig. 1) . This makes up the major portion of the prion protein POM6 epitope. The other binding regions of the prion protein constitute some smaller segments of the a1 and a2 helices. Helix a3 of the prion protein binds predominantly to the heavy chain of the POM6 Fab. Interestingly, residue Glu199 at the amino terminus of helix a3 of the mouse prion protein engages in many interactions with residues from all three of the heavy chain CDRs of the POM6 Fab (Figs 1, 2 and Table 2 ). These include hydrogen bonding interactions with the side chain NE2 atom of His34 from CDR H1, the backbone amide of Asp100 from CDR H3 as well as a salt bridge interaction with the NH1 of Arg49 of CDR H2 (Table 2 ). In the carboxy-terminal region of the loop connecting the a2 and a3 helices of the prion protein there are contacts with the CDR H3 of the POM6 Fab. The backbone amides of Glu199 and Thr200 and the side chains of Thr198 and Thr200 from the prion protein make critical hydrogen bonds with residues Gln99 and Asp100 from the CDR H3 (Fig. 2) . Other interactions between the POM6 Fab and the prion protein involve residues Lys203 and Glu206 on helix a3 of moPrP; they make a network of hydrogen-bonding interactions with Asn51 from the heavy chain CDR H2 and the backbone carbonyl oxygen of Thr29 from heavy chain CDR H1. Glu210 on helix a3 of the prion protein also contributes to the interactions with the POM6 Fab heavy chain by forming a hydrogen bond with Tyr53 of the heavy chain CDR H2. The only residue on helix a1 of the moPrP that makes contact with the heavy chain of POM6 Fab is Glu145 through a longish hydrogen bonding interacts with residue Gln99 in CDR H3.
The light chain of the POM6 Fab predominantly binds to residues on helix a1 of the mouse prion (Fig. 2) . This confirms previous epitope binding studies that showed that the POM6 Fab competes with the POM1 Fab (epitope residues 139-144) for the prion protein binding [10] . There are only four hydrogenbonding interactions between residues of the POM6 Table 2 ).
Fab light chain and the mouse prion protein. Two of those bonds involve Tyr148 and Glu151 from helix a1 with Try36 and Tyr34, respectively, from the CDR L1 of the light chain of POM6 Fab. The other two interactions involve Thr200 on helix a3 and Asn196 on the loop joining helices a2 and a3 with Lys54 of the light chain CDR L2 and the backbone carbonyl oxygen of Trp96 from the CDR L3 respectively. The rest of the interactions between helix a1 and the POM6 Fab take place in a 'binding pocket' that is confined by helices a1, a3, the a2 to a3 loop and CDRs L1 and L3 of POM6.
As glycerol was used as the cryoprotectant for the moPrP:POM6 Fab protein complex crystals, we observed the electron density for one glycerol molecule in the 2|F O |À|F C | map in the center of the binding pocket. Within this pocket, Tyr148 of helix a1 forms a hydrogen bond with Tyr36 from the light chain CDR L1 and with the glycerol molecule. The glycerol molecule also forms stable hydrogen bonds with residues Tyr148, Asn152, Arg155 from helix a1, Asn196 from the a2 to a3 loop and Asp201 from helix a3. This network of salt bridges and hydrogen bonds orients helix a1 toward helix a3 and keeps the hydrophobic core intact. The presence of the glycerol molecule in the binding pocket does not induce the formation of any new interactions but merely serves to consolidate the existing ones. Table 2 summarize all of the significant intermolecular interactions (less than 4.0 A in distance) in the protein complexes of moPrP:POM6 Fab and moPrP:POM1 Fab.
N-Glycosylation attachment sites
There are two Asn residues in moPrP that constitute the N-glycosylation sites, Asn180 in helix a2 and Asn196 in the loop connecting helix a2 to helix a3. In Table 1 . Data collection and refinement statistics. The data in parentheses refer to those reflections in the highest resolution shell.
where ‹I(hkl)› is the mean intensity for multiply recorded reflections. the protein complex of moPrP:POM6 Fab, Asn180 forms a hydrogen bond with Asn54 from CDR H2 and Asn196 from the prion protein forms a hydrogen bond with the backbone carbonyl oxygen of Trp96 in CDR L3. These molecular interactions are present on the boundary of the antigen-antibody recognition interface. Previous studies have shown that POM6 interacts with nonglycosylated, mono-glycosylated, and diglycosylated versions of the mouse prion protein [10] . These N-glycosylation versions influence the expression as well as the localization of the cellular prion in different regions of the brain [16] . The glycan likely affects the conformation of the PrP C ; its probable role in the malicious changes into PrP Sc has been established [17, 18] . Similar to that of moPrP:POM6 Fab, in huPrP:ICSM18 Fab (PDB ID: 2W9E) and in ovPrP:VRQ14 Fab (PDB ID: 1TQB) the glycosylation sites are in close contact with the CDR regions of the cognate antibody Fab molecule (Fig. 3) . As the antigen-antibody complexes were prepared by using the recombinant prion molecules devoid of any attached glycosylation, the Asn residues are available to make direct molecular contacts to the CDR regions. In a manner similar to what we have observed in the moPrP:POM6 fab complex, the Asn residues are also partially accessible in the protein complexes of huPrP: ICSM18 Fab and in ovPrP:VRQ14 Fab. These Asn residues could adopt several side-chain conformations in the different glycosylated isoforms of the PrP C . The side chain of Asn196 is located in the loop between helices a2-a3; this residue could have more flexibility compared to the side chain of Asn180 present on helix a2. For the in vivo binding to the glycosylated PrP-isoforms, the attached glycans to the Asn residues would have to move to a different orientation in order to allow the antibodies to bind to their respective epitopes. The N-glycan moiety can be quite heterogeneous in its composition having different branching patterns, varying degree of carbohydrate chain length along with the use of a wide variety of sugar molecules [19] . Due to the antibody binding the flexibility of the glycans would be reduced greatly even though they still can accommodate a varied degree of complexity. We speculate the POM6 Fab could bind to the glycosylated isoforms similarly to that of the binding mode observed in the POM6 Fab:moPrP crystal structure with minor conformational changes to the Asn side-chains and to its interacting flexible CDR regions. The majority of the molecular interactions between the POM6 Fab and the moPrP would remain unchanged.
Electrostatic interactions
Analysis of the electrostatic potential surface map of the interacting interface of moPrP with the POM6 Fab complex shows the interactions are predominantly electrostatic in nature. The electrostatic nature of the surface presented by the prion molecule for Fab binding results from negatively charged residues whereas that presented by the POM6 Fab CDRs is mostly positively charged (Fig. 4) . Residue Glu199 from helix a3 of the prion protein makes salt bridge interactions with Arg49 and His34 of the POM6 Fab heavy chain. Interestingly, the negatively charged residue Asp100 in the CDR3 of the heavy chain is positioned in order to make a stabilizing electrostatic contact toward the positive electrostatic helix dipole moment of helix a3 of the prion protein. Lys53 and Lys54 of the POM6 Fab light chain contribute to the positively charged binding interface. Analysis of the interactions using LIGPLOT [20] showed that the majority of the interactions that promote the stability of the moPrP:POM6 Fab complex are contributed by the side chains of the residues from Glu199, Lys203 and Glu206 on helix a3 and by Trp144 and Tyr148 on helix a1. The moPrP molecule makes 11 crystal contacts with neighboring symmetry related molecules. With the exception of Tyr154 in helix a1, the remaining ten residues involved in the crystal contacts are far from the POM6 binding regions of the moPrP. The majority of the crystal contacts are in the carboxy-terminal region of helix a3 and one crystal contact each in helix a2, strand b2 and in the b1-a1 loop.
Discussion
It is typically very difficult to target protein-protein interactions with small molecules, whereas protein- based therapeutic agents such as antibodies and nanobodies can be more effective due to their larger contact surface areas and stronger binding affinities. Antibody based therapy has gradually become the mainstay therapeutic agent for many disease classes due to their uniqueness in recognizing the targets [21, 22] . This is particularly true for the prion protein, and antibodies have been considered the most effective anti-prion agents since the first demonstration of their efficacy in vivo [23] . Biological responses from organotypic cerebellar slice experiments on several anti-prion monoclonal antibodies which target different prion epitopes is quite interesting and differ greatly based on their epitope recognition sites [10, 11] . Antibodies that target the unstructured domain of the prion protein are mostly therapeutic in nature, whereas monoclonal antibodies that target the structured domain are either toxic or innocuous as observed in the cerebellar slice experiments. The POM1 antibody that recognizes mainly the residues of helix a1 of the prion protein and its Fab as well as ScFv fragments are all found to be toxic, whereas the POM6 antibody is innocuous [11] . These observations perhaps hold the key to which regions of the prion protein are susceptible to malicious conformational changes upon slight structural alteration. Structural changes in the prion protein upon antibody binding are likely to be crucial in determining either stability or a malicious mis-folding event resulting in prion propagation and/or toxicity.
Structural comparisons of moPrP:POM6 Fab and moPrP:POM1 Fab
A comparative structural analysis of the complexes of the moPrP:POM6 Fab and moPrP:POM1 Fabs (PDB ID 4H88) may give clues toward the source of the functional differences between the two antibodies. The binding of POM6 Fab buries a surface area of 805 A 2 on the moPrP molecule and involves binding to all three of the a-helices, whereas the binding of POM1 buries an area of only 611 A 2 , involving primarily the C-terminal part of the b1-a1 loop and N-terminal part of helix a1, and three residues from helix a3. A backbone carbon atom (Ca) alignment of the structures of POM6 Fab bound to moPrP125-225 and POM1 Fab bound mouse moPrP120-231 resulted in an r.m.s.d. of 0.621 A (for 100 common Ca-atom pairs) (Fig. 5) ; this shows that neither of the Fabs significantly alters the overall structure of the globular domain of the moPrP. The comparison of several of the local structures of the Fab bound PrP molecules however, reveals interesting changes in the intra-and interdomain interactions within the globular domain of the prion protein molecule that could reveal the source of the toxic behavior of the POM1 antibody.
The compact association of the b1-a1-b2 and a2-a3 subdomains of the prion protein molecule seems to be important in preventing the malicious mis-folding event. Domain swapped dimers of the prion protein observed in a crystal structure had swapping of helix a3 between monomers, indicating a possible separation between the domains [24] . In a completely different experiment, the chemically tethered b1-a1-b2 and a2-a3 subdomains prevented prion pathogenesis upon scrapie challenge [25] . A major portion of the two subdomain contacts lies between the C-terminal part of the b1-a1 loop and helix a1 making contact with Nterminal part of helix a3. In addition to the extensive hydrophobic contacts through Phe140, Tyr148, Tyr149 of the b1-a1-b2 region, with the hydrophobic residue Met204 of the helix a3 few additional interactions are present in the moPrP:POM1 Fab structure because of the POM1's unique binding. An intermolecular salt bridge interaction is present between residues Lys203 and Glu145 of moPrP (Fig. 6) . The POM1 Fab's binding also facilitates a hydrogen-bonding interaction between the Arg207 side chain and the main chain carbonyl group of His139. These structural alterations of the loop region of the b1-a1 are not observed in the crystal structures of the mouse prion protein from the moPrP:POM6 Fab complex nor in the crystal structures of huPrP (PDB ID: 3HAK) nor in the crystal structure of huPrP bound with ICSM18 Fab (PDB ID: 2W9E). The structured domain of huPrP and moPrP share a sequence identity of 91%. Due to the unavailability of the crystal structure for the mouse prion in unbound conformation, these human prion crystal structures were used as the reference for our analysis. The hydrophobic contacts between the residues involved, from the b1-a1 region and the hydrophobic residues from helix a3 are affected due to the interaction of POM1 Fab. Residues Met134 and Pro136 from the b1-a1 loop do not make closer hydrophobic contacts with Val208 and Met212 in the POM1 Fab bound structure whereas a compact arrangement of these core hydrophobic residues is observed in the moPrP:POM6 Fab structure (Fig. 7) . These changes in the hydrophobic contact could possibly be the effect of crystallization condition as well as crystal packing differences in POM6 and POM1 Fab bound structures. Interestingly, in the POM1 bound structure, the b1-a1 segment where noncompact hydrophobic contacts are observed is making a crystallization contact with the same segment from another moPrP molecule. This segment of moPrP in moPrP: POM6 Fab complex does not make any crystallization contacts. Several pathogenic mutations are located in the hydrophobic core of the prion protein [26, 27] . Upon POM1 Fab binding the stabilizing salt bridge interactions involving Arg155 and Glu195 between the b1-a1-b2 and a2-a3 subdomains are lost. This salt bridge interaction has been ascribed to be the origin of mis-folding and can be influenced by the pH of the environment [28] . In the crystal structures of all huPrP molecules, this salt bridge interaction is observed to be intact despite the fact these human prion proteins were crystallized under very different conditions. Several experimental studies have implicated the b2-a2 loop of the prion protein in playing a role in prion transmission across species [9, 29, 30] . The nonlocal salt bridge between residues Arg163 and Asp177 has been shown by molecular dynamics simulation studies to be highly populated with a 90.4% occupancy [31] . This salt bridge firmly anchors the short b2 strand of PrP to helix a2. The Arg163-Asp177 salt bridge is present in the moPrP:POM6 Fab but not in the moPrP:POM1 Fab (Fig. 8) . In moPrP:POM6 Fab, we also see that the buried Tyr168 of the b2-a2 loop forms hydrogen bonds with both of the residues of the salt bridge Arg163-Asp177. In the moPrP:POM1 Fab, however, Tyr168 forms a hydrogen bond with only residue Asp177. A second tyrosine residue, Tyr127 of the amino terminus of moPrP forms cation-pi interactions with Arg163 but a much weaker interaction in the POM1 bound moPrP. In moPrP:POM6 Fab, Tyr127 forms an additional critical hydrogen bond to Asp177 on helix a2. The Asp177Asn mutation is associated with FFI and familial CJD depending on the amino acid in position 127 [32, 33] . In the Asp177Asn mutation, the hydrogen bond between residues Tyr127 to Asp 177 would be abolished. The Tyr127 to Asp177 serves to anchor the flexible amino terminus of the globular domain of PrP to helix a2 [31] . In the moPrP: POM1 Fab complex, Tyr127 is too far to form a hydrogen bond with Asp177. Interestingly, with the exception of the salt bridge between Arg163 and Asp177, the above described network of interactions amongst residues Arg163, Tyr168, Asp177, and Tyr127 in the b2-a2 loop is also seen in the Promazine bound structure of the moPrP:POM1 Fab complex (PDB ID: 4MA7) [34] . This network of interactions has been suggested to make the b2-a2 loop more stable. This region of moPrP does not make any crystallization contacts with neighboring molecules in moPrP:POM6 Fab whereas in moPrP:POM1 Fab complex crystal structure a few interactions are present from the neighboring molecule. Judging by the additional interactions, the b2-a2 loop in moPrP:POM6 Fab appears more stable than the one in moPrP:POM1 Fab. It should also be noted, that similar orientations for this loop to that of the POM1 Fab bound moPrP have been observed in the PDB structure of the ICSM18 Fab bound with the human prion protein [35] which seems to cause dose dependent neurotoxicity [36] . Furthermore, the regions of the C-terminal part of helix a3 near to the b2-a2 loop in the moPrP:POM1 Fab has an angular shift of 9.6 degrees compared to the Cterrminus of the moPrP in the moPrP:POM6 Fab complex without any significant changes through the crystal contacts (Fig. 5B ). This displacement of helix a3 toward the b2-a2 loop appears to provide hydrophobic contacts and likely compensates the loss of stabilizing interactions from the Tyr127 of strand b1.
The small b1-b2 region just adjacent to the b2-a2 loop region is another important part of the prion protein in imparting stability to the structural domain of the PrP C . In this small antiparallel beta-sheet the sidechains of residues 129 to 131 (Tyr-Met-Leu) (YML) and of 161 to 163 (Tyr-Tyr-Arg) (YYR) make extensive hydrophobic contacts with one another. The hydrogen bonding interaction of Tyr127 of strand b1 with Asp177 from helix a2 further consolidate these contacts. Loss of this hydrogen bonding interaction between these two residues will result in less extensive hydrophobic contacts and a weaker b1-b2 region. Nuclear magnetic resonance spectroscopic experiments have also corroborated a loosening of the b1-b2 region upon POM1 binding [11] . The YYR motif in strand b2 has been previously shown to be exposed in PrP Sc indicating an opening of this substructure during the mis-folding process [37] .
The molecular changes in the moPrP structures described above upon different antibody binding could be minimally influenced by several extrinsic factors. More structural data are needed at this point for a convincing conclusion regarding the structural aspects of POM1's toxicity. Nevertheless, the molecular structures of the POM6 Fab with the moPrP structured domain complex have been successfully solved at a resolution of 1.83 A. The POM6 Fab has a unique epitope on the globular domain of moPrP making it one of the first anti-PrP antibodies to be shown to bind to all three a-helices of the cellular PrP C . One of the major local structural changes that take place in the moPrP molecule upon POM6 Fab binding is in the b2-a2 loop where a network of hydrogen bonds and salt bridges between key residues creates a multitude of stabilizing forces that are comparable to the prion molecular structure stabilized with the anti-prion promazine molecule. Upon comparison of the structures of the toxicity inducing POM1 Fab complex with the POM6 Fab complex it has become apparent that the toxic antibody only targets a smaller region of the prion protein and tries to distort selectively the core of the structured domain. The compact core of the structured part of the prion protein must not be altered by anti-prion therapeutics. Therapeutic targets must be aimed for an overall stabilization of the many disorder prone regions in PrP C . The mis-folding vulnerabilities within the prion protein subdomains highlighted in this study will help to pave the path for future antiPrP therapeutics.
Materials and methods

Production of POM6 IgG and Fabs
The IgG1 POM6 hybridoma was prepared according to Polymenidou et al. [10] . After hybridoma cell culture the antibody was enriched and the cell free medium was loaded on to a protein G Sepharose column. The POM6 antibody was eluted with 0.1 M glycine, pH 2.8. For the Fab production, the IgG1 POM6 (1 mgÁmL À1 ) was digested with papain at a POM6/papain ratio of 1/0.02(w/w) in 50 mM , Tris pH8.0, 150 mM NaCl, 20 mM EDTA and 20 mM cysteine. Papain was inactivated by the addition of 30 mM iodoacetamide after 5 hrs of incubation at 37°C in a water bath. The POM6 digest was then concentrated and the buffer exchanged with the Protein A IgG binding buffer (Thermo Scientific) and loaded onto a protein A sepharose column (Pierce). The Fc fragment and the undigested IgG1 POM6 remain bound to the protein A column, whereas the POM6 Fab fragments were collected in the flow through. The Fab fractions were exchanged to 50 mM ,Tris 150 mM NaCl, pH 8.0, concentrated and finally assessed for homogeneity by Coomassie brilliant blue staining following separation by SDS/PAGE.
Construction of moPrP clones
The moPrP segment from residue 125 to 225 was constructed by using the polymerase chain reaction (PCR) having restriction sites BamHI and EcoRI at the The PCR product was purified on a 1% agarose gel and extracted for restriction endonuclease digestion at 37°C for 2 h with BamHI and EcoRI. This segment then cloned in the pRSET-A vector (Invitrogen) using restriction sites BamHI and EcoRI that also contains a Thrombin cleavage site at the amino-terminal histidine tail. The same conditions were also used to digest the pRSET-A vector with BamHI and EcoRI. The digested products were gel purified and ligated to obtain PrP125-225 in the pRSET-A vector. Competent DH5a cells were transformed with the ligation product and plated on Agar-LB medium with Ampicillin (100 lgÁmL À1 ). A colony PCR was performed for randomly picked colonies to identify the clones having the desired construct. Plasmids were extracted from the positive clones and their sequences were verified
Expression and purification of PrP constructs
Overnight cultures of freshly transformed colonies of BL21 (DE3) cells (Stratagene) with PrP125-225 were added to LB media with 100 lgÁmL À1 of ampicillin at 37°C with constant shaking at 250 r.p.m. At an OD600 nm of 0.5, the expression of the prion protein was induced with 1 mM of IPTG. The induction was allowed to proceed overnight at 30°C after which the cultures were harvested. The cells were resuspended in 1xTBS pH 8.0 and sonicated. The solubilized inclusion bodies of PrP125-225 was loaded onto a Ni-IMAC column. The bound moPrP was refolded on-column with a 200 mL gradient of buffer U (8M Urea, 10 mM Tris, 100 mM Na 2 HPO 4 pH 8.0) to buffer B (10 mM Tris, 100 mM Na 2 HPO 4 pH 8.0). The refolded protein was washed on-column with buffer B containing 50 mM imidazole. Purified moPrP was eluted with 10 mM Tris, 100 mM Na2HPO4, 500 mM imidazole pH 5.8 and dialyzed into water. For the cleavage of the amino-terminal histidine tag, cleavage buffer of 50 mM Tris, 10 mM CaCl 2 pH 8.0 was added to the protein. One unit of Thrombin enzyme was added to every 1 mg of protein to be cleaved and the cleavage reaction was allowed to proceed overnight at room temperature.
Crystallization of moPrP:POM6 Fab complex
Purified POM6 Fab was mixed with twofold molar excess of His-tag cleaved moPrP and concentrated to 15 mgÁmL with the microseeding technique resulted into larger-sized regular-shaped crystals. Diffraction quality crystals were obtained in 0.2 M sodium malonate pH 7.0, 12% PEG8000 along with 5 mM TCEP, 5 mM praseodymium acetate and ethanol as additives. The crystals were then flash-frozen in liquid N 2 after adding 30% glycerol as a cryoprotectant.
Structure solution and refinement
Intensity data were collected at wavelength of 0.97949 A from a single crystal at the bending magnet beamline (08B1-1) of the Canadian Light Source (CLS), Saskatoon [38] . The resolution of the data was 1.83 A with an overall completeness of 99.8%. For data processing, scaling and integration, the XDS program was used [39] . The crystals were indexed in the orthorhombic space group P22 1 2 1 with one molecule in the asymmetric unit. The structure of moPrP:POM6 Fab was solved by molecular replacement using the program PHASER of the PHENIX suite [40] with the POM2 Fab protein as the search model (PDB ID: 4J8R). Around 87% of the model was built by using AUTOBUILD of the PHENIX suite [41] ; the remaining part of the model was built manually by fitting to the electron density in the |2|Fo|À|F C ||, a calc map. The data processing and refinement statistics are summarized in Table 1 . The PHENIX suite was used to perform crystallographic refinement on the molecular model of the moPrP:POM6 Fab complex [42] . Five percent of the reflections from the measured data were randomly selected and set aside to calculate the R free factor for monitoring the progress of refinement. The positions of water molecules were initially identified using PHENIX and their positions were subsequently confirmed by manually checking for positive peaks in both the 2|Fo|À|F C | and the |Fo|À|F C | electron density maps. Clear electron density was observed for the glycerol molecules whereas for the additive praseodymium acetate there were no identifiable density in the refined map. Water molecules with refined B-factors greater than 60 A 2 were removed from the coordinate list. The program COOT was used for manual model building [43] . Structure validation was performed with the program MOLPROBITY [44] . Potential hydrogen bonds and van der Waals contacts were analyzed using the program LIGPLOT [20] . The final coordinates and structure factors of the moPrP:POM6 Fab have been deposited in the RCSB protein data bank with the accession number 6AQ7.
